Asia-Pacific Animal Stem Cell Therapy Market by Trends, Key Players, Driver, Segmentation, Forecast to 2025 – Latest Herald

Hongchun Research latest addition on Asia-Pacific Animal Stem Cell Therapy market is a research that features comprehensive outlook pertaining to market valuations, market share, profit estimations, and the geographical spectrum of this business. The report precisely describes key obstacles and opportunities for growth, while drawing out competitive standing of market majors, including their portfolio and growth strategies.

Get PDF Sample Copy on Global Animal Stem Cell Therapy Market @https://hongchunresearch.com/request-a-sample/1025

According to the Global Animal Stem Cell Therapy Market Report, the Animal Stem Cell Therapy Market is expected to witness steady to high growth rate owing to the increased demands from various industries, as well as the regions which are developing at a quick pace. The buying capability and rise in disposable incomes is also a major factor here affecting the Global Animal Stem Cell Therapy Market positively. The Global Animal Stem Cell Therapy Market Report covers the rest of the current trends / opportunities / challenges in substantial detail.

Market Segmentation is one of the key factors of any Market Report. The Global Animal Stem Cell Therapy Market report ensures that the customers receive detailed information of all the Animal Stem Cell Therapy market segments and sub-segments, and hence are covered in a much elucidated fashion. The Global Animal Stem Cell Therapy Market is segmented into various types such as by product, application, end users, and regions.

The global Intelligent Intravenous Infusion Pumps market report is a comprehensive study that encompasses top manufacturers, prospective market share, revenue, purchaser volume with respect to dealing volume and global segmentation for the Intelligent Intravenous Infusion Pumps industry. The report further includes market classification and definitions, product and industry overview, manufacturing specifications and cost structure, included raw materials and so on.

In addition to the vast definitive data, the report also sheds light on the past behavior of the market and an upcoming growth graph that is expected to venture in an upwards trajectory despite market fluctuations and trends.

Access Research Report on Global Animal Stem Cell Therapy Market @ https://hongchunresearch.com/report/asia-pacific-animal-stem-cell-therapy-market-1025

Market Segmentation:The Intelligent Intravenous Infusion Pumps report follows an accumulated research methodology that is based on years of experience combined with structured data points acquired from proprietary sources. These methods function with thorough research and analysis split between primary and secondary research combined with an in-house data wrangling process. In general, the data points are gathered from a variety of sources such as vendor projections, product list, research papers and a detailed list of manufacturers. The analysis is than derived into quantitative market values such as qualitative and quantitative qualities, market forecast models, market segmentations and business models that revolve around the Intelligent Intravenous Infusion Pumps industry.

Moreover, the Intelligent Intravenous Infusion Pumps market report clarifies the market segmentation based on various parameters and attributes that can be classified on geographical region, product types and market applications.

The reports shows the different typesvolume and Value in different applications. The major Intelligent Intravenous Infusion Pumps Market (The Northeast, The Midwest, The Southwest, The Southeast, The West) is analyzed, data including: market size, import and export, sale segment market by product type and applications.

Market Analysis by PlayersBDAbbott LaboratoriesSmiths MedicalB. BraunHospiraBaxterMoogCareFusionMindrayZollIradimedTeleflexMedlineZyno MedicalMaxim

Market Analysis by Regions:The NortheastThe MidwestThe SouthwestThe SoutheastThe West

Market Analysis by Types:Constant Volume Control TypeSyringe Injection TypeOthers

Market Analysis by Applications:HospitalClinicOthers

The report also focuses on developing market trends, preferred market channels and market drivers & restraints to name a few.

Get More Information on Global Animal Stem Cell Therapy Industry @ https://hongchunresearch.com/enquiry-before-buying/1025

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

Original post:
Asia-Pacific Animal Stem Cell Therapy Market by Trends, Key Players, Driver, Segmentation, Forecast to 2025 - Latest Herald

Covid-19 impact on Life Science Reagent Market Analysis and Forecast 2020|Abcam,Emd Millipore,Biolog,Cell Sciences – Cole of Duty

The global Corona impact on Life Science Reagent Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Life Science Reagent Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Life Science Reagent Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Life Science Reagent Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Life Science Reagent Market.

Leading players of the global Life Science Reagent Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Life Science Reagent Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Life Science Reagent Market. It also provides useful recommendations for new as well as established players of the global Life Science Reagent Market.

Request for Sample Copy of This Report @https://www.reporthive.com/request_sample/2292975

Major Players:

High Throughput Genomics Inc.Illumina Inc.Abbott LaboratoriesAbcamEmd MilliporeBiologCell SciencesLonza Group AgCell Signaling TechnologyThermo Fisher Scientific Inc.Trilink BiotechnologiesCepheid Inc.Olympus Corp.Biomyx TechnologyAbgent Inc.

Segmentation by Product:

Cell Biology ReagentsAnimal ModelsRecombinant ProteinsOthes

Segmentation by Application:

Stem Cell ResearchDNA ResearchRNA ResearchProtein DetectionOthers

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2292975

Competitive Analysis:

Global Life Science Reagent Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Life Science Reagent Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Scope of the Report:The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Life Science Reagent Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The key insights of the Corona impact on Life Science Reagent Market report::

The report provides key statistics on the market status of the Life Science Reagentmanufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The report provides a basic overview of the industry including its definition, applications and manufacturing technology. The report presents the company profile, product specifications, capacity, production value, and 2014-2019 market shares for key vendors. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report estimates 2020-2026 market development trends of Life Science Reagent industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. The report makes some important proposals for a new project of Life Science Reagent industry before evaluating its feasibility.

Why Report Hive Research:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Touch With Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Here is the original post:
Covid-19 impact on Life Science Reagent Market Analysis and Forecast 2020|Abcam,Emd Millipore,Biolog,Cell Sciences - Cole of Duty

State of the University Address – USC News

April 29, 2020

Hello and welcome Trojans.

Its such a privilege to speak with you today, about the state of our university, the times were in, and about our future a bright and promising one.

Thank you for attending this event; I hope you and your families are well.

Students are joining us for the first time; to them I say, welcome and Ill address you directly at the end of my speech.

I never expected to make history by Zooming this event and I would much prefer seeing and chatting with you before and after the talk. But Im confident those days too will return.

First though, I want to talk about the obvious. COVID-19 has hit us hard.

I know people are hurting and worried. Many are out of work. Thousands are in hospitals. Too many are dying, and it is heartbreaking.

Our people at USC are hurting too.

Your schedules and plans have been disrupted. Cherished events, like performances, competitions, thesis defenses, and commencement, have been postponed or changed. An entire athletic season has been erased. Youre missing friends, colleagues, and family you havent seen for weeks.

Some of you are working or studying from homes that werent prepared for this crisis, perhaps surrounded by people who need your attention or help.

Others are coming in to work, to help people still on campus, in spite of their own fears of the disease.

And I know, were all missing the joy and energy of being with our fellow students, colleagues, and friends.

It can feel very dark right now, but I see Trojans stepping up in this crisis every single day, under very difficult circumstances.

Im in awe of all of you.

Your strength is a beacon of hope.

Here are a few snapshots of that hope out of hundreds, I could cite

Ill start with our healthcare workers, in our hospitals, pharmacies, and clinics you heroically transformed yourselves overnight, to meet the pressing needs of patients throughout our region, prepare us for a surge, and advise the university about how to protect safety.

Faculty and staff, you swung into action, re-organizing completely the way you taught, mentored students, and went about your work.

Within five days, more than 6,000 courses were being reimagined and delivered remotely.

Our student life and housing staff helped 1,600 students who couldnt go home, to stay safely in their dorms. We began the Care-for-the Caregiver program, and are providing beds for USC and LA County health care workers. And our emergency staff began taking care of everyone.

The common denominator in all these examples, is a spirit of service and selflessness that animates so much of what we do.

For 140 years, USC has been part of the fabric of our region, and our city. And from the start of the crisis, Trojans have joined hands with community-based organizations, to support our most vulnerable neighbors.

USCs tireless volunteers delivered tens of thousands of meals to our neighbors, including those without shelter. Theyve made all sorts of PPE, provided two meals a day to our 500 Head Start kids and their families, organized a blood drive, and are helping nearly 3,000 small businesses to survive.

We see that same spirit of service in the remarkable work of our researchers, who are moving with lightning speed, to advance clinical trials, drug and vaccine development, pre-clinical therapeutic studies, and expand COVID-19 testing.

Theyre also helping people directly, providing telemedicine mental health counselling, and assisting public schools to adapt to COVID-19, and so much more.

Chances are, if youve heard about it, someone at USC is working on it and this is thanks in large part to COVID-19 innovation funds, created by the Provost, and added to, by generous parents, friends, and alumni from around the world.

Over my entire professional career, Ive never seen researchers and innovators come together, so quickly and with such purpose. I truly believe that in the end, science and human ingenuity, and care, will beat this.

COVID-19 may have knocked us hard but its also revealing sides of ourselves we may not have seen before.

As a biologist, Im reminded of the history of the microscope. Just over 400 years ago, Galileo, the extraordinary innovator he was, saw the power of magnifying lenses being made by Dutch master crafters and he used the lenses to complete the first microscope.

All of a sudden, the vast world of tiny organisms never seen before, became open to us, and just like that, human thinking was altered forever.

A year later, Galileo also perfected the telescope, expanding humanitys view into the universe, again changing forever what could be imagined.

One of the things I love most about teaching, is seeing my students reach that moment of clarity, when their understanding becomes crystal clear, and their horizons broaden.

I am seeing this in all of you, right now.

We are experiencing our own Galileo moment.

Were seeing problems as opportunities, exercising muscles we didnt know we had, tapping into wells of expertise and knowledge and compassion we didnt know were so deep.

Our entire workforce has turned on a dime, finding new ways to work together and solve problems, and helping people faster and more flexibly than ever before.

I believe now that weve seen and put these capabilities to use, in service of something bigger than ourselves, we wont, nor could we, go back.

This is what it feels like to collaborate at warp speed something Ive talked about before.

We see this happening so fully at USC because our community has been changing for some time now and, in important ways.

Weve been transforming our culture, our structure, and our governance, to enable us to become the university of the future and these changes are benefiting us now, as we adapt to meet the COVID-19 crisis.

So, let me turn to some of our key achievements that are driving a bold new vision for USC, for the coming decade. A full compilation of these accomplishments will be available on the USC website.

Ill start with our students, drawing on 48,000 individual stories, of achievement and cultural diversity.

USC has one of the most diverse student populations, and largest financial aid programs almost $650 million last year alone of the leading research universities in America.

And our incoming class, drawn from almost 60,000 talented applicants, is shaping up to be as accomplished and diverse as ever.

In fact, both Viterbi and Marshall are leading the nation among top-ranked schools, by welcoming classes at roughly gender parity.

Our students continue to say, they are coming to USC because it is the best place for them, to explore and pursue their passions, improve communities, and become game-changers.

Here they have the chance to work with some of the greatest minds of our times, and to get involved in so much.

This year, our students won numerous prestigious awards, with their talents on display in so many amazing ways.

They perform on Broadway, conduct ground-breaking research, write music, invent things, win competitions, and launch rockets. They volunteer their services and run businesses, and evaluate capital markets. They provide free legal clinics and medical and dental care. And they help feed, design, and house those without homes.

As graduates, theyll have an even bigger impact on their communities and in their fields, as our alumni always have.

USC is distinguished by its extraordinary breadth and strength. We see it, in our 23 academic units, in nearly $900 million in competitive research, and in our 28,000 graduate and professional students, and roughly 8,000 faculty.

The number of leading, top 10, and top 20 rankings received, by USC, our schools, and our departments, grew again this year.

Keck was ranked for the first time, as one of Americas top 20 hospitals. Childrens Hospital Los Angeles (CHLA) ranked number one in California, number one in the western United States, and number five in the country is the only leading childrens hospital that is a safety net hospital with more than 70 percent of its patients on Medicaid.

Reuters designated USC the eighth most innovative university in the world, and our graduates are often named Forbes 30 under 30 game-changers, in fields from arts to tech.

Our faculty continued to receive prestigious national honors including eight USC additions to the national academies of engineering, sciences, and inventors. Wow.

Theyre writing books and papers, changing the course of science, humanities, and policy. Theyre performing on stages worldwide, launching new companies, and pushing the frontiers of stem cell research. Theyre pushing to cure Alzheimers, cancer, and helping people to see again. Theyre leading the way in emerging fields, like Immuno bio-engineering, and working to end the educational, social, health, and economic disparities that plague our world.

And of course, all our achievements happen in partnership with our nearly 28,000 wonderful, determined, and dedicated staff many of whom are also our alumni. Im proud of the fact that we are the largest private employer in Los Angeles.

Our staff run our services from transportation to hospitality. Theyre part of our research and our teaching teams, they take care of our finances and our campuses; they keep us safe and our IT secure, they coach and care for our athletes.

They also care for our health and well-being, manage our operations, and organize our events. And they help us communicate, work with our stakeholders, and raise much needed financial support.

Our staff and faculty are incredibly generous as well, and I want to call this out. This year, we celebrated 25 years, during which thousands of our employees, donated 1 percent of their own salaries to support our Good Neighbors Program, to the tune of more than $26 million.

We also welcomed Chief Alma Burke, the first Latina and first female to serve as an Assistant Chief in USCs vitally important Department of Public Safety.

Finally, no State of the University speech would be complete without acknowledging the strength that comes from the Trojan family. Our alumni, parents, friends, and others are on the frontlines with us all the time, and they give generously to support our university.

USC simply wouldnt be who we are, without our alumni and their love of this very special place. They serve with great distinction, on our councils, in our Centers, and on our Board of Trustees.

Looking ahead, we know COVID-19 will continue to challenge us for some time. But I promise you, it will not deter us from reaching our goals.

Instead, we must take everything were learning in the fight against the pandemic like our newfound strength in collaboration, our willingness to change, our fresh perspective about where we are going and use it, to accelerate our transformation.

Specifically, we need to apply this knowledge and experience to deepen culture change, reinforce high ethical standards, and restructure our governance for a new, multidisciplinary, collaborative age.

Last September, I laid out four strategic goals for the university, and were making good progress here.

The first goal is to open our doors wider for students from all backgrounds. We want to make sure they truly flourish at USC, and become the leaders who build and succeed in the new economy.

Were making good on the historic pledge we made in the fall, to provide significantly more financial aid to low income students.

Were also on the way to doubling the mental health professionals at the student health center, expanding programs for First Gen, transfer, and undocumented students, and designing new spaces for student cultural groups, that do not currently have homes.

Our second goal is to take on sustainability, like never before, and build expertise that can reach around the world.

You may have heard about nature, returning to our locked-down cities along with clean air. Here in LA, once again, you could stand in one spot, and marvel at the crisply defined mountains to the east, and the sparkling Pacific Ocean to the west.

It reminds us what is possible, but it also shows us how much more we must do in the area of sustainability, to foster the kind of environment that will nurture us, and bring us joy.

Im proud of how far USC has come this year my zero-waste inauguration diverted an estimated 4,500 pounds of waste, from local landfills. Over 90 percent of waste is diverted at the Coliseum now, and I look forward to setting similar bold goals for the university overall.

Were on track to engage 75 percent of our departments in responsible purchasing, so that we can phase-out single use, non-essential plastics.

Were aggressively, pursuing a timeline for carbon neutrality, installing solar panels, subsidizing public transit, and supporting sustainability innovation funds.

And in just a few months the Presidential Working Group on Sustainability united around a number of recommendations to create the governance and educational programs, that will best help USC become a leader in sustainability.

Our third goal is to deepen our public partnerships, and become the leading university in reimaging the urban future. Here too, we are well on our way.

The COVID-19 crisis accelerated our efforts, to build and strengthen partnerships with city, county, state, and federal leaders.

It also put in stark relief, persistent inequalities in our society, that are having deadly effects, particularly in underserved communities of color.

For USC to be a leader in the urban future, we cant limit ourselves to being part of the recovery and building out of new economies; we also must be partners in the development of solutions to eliminate these enormous and destructive inequities.

For example, education and health systems need to accelerate efforts, to narrow disparities in the communities they serve, with solutions that can make a lasting difference.

As just one example, Im proud of the multidisciplinary efforts underway at Keck Medicine and the School of Medicine, to increase diversity in clinical trials.

They are energetically recruiting participants from areas of Los Angeles with large Latino populations, so they can be better represented in cardiac surgery clinical trials. This could go a long way in improving cardiac care for a large population.

And the fourth goal is to leverage the formidable talent of our faculty and schools, by pursuing bold ideas in areas where USC has a distinct advantage.

Our people are already hard-at-work considering moonshots, in big data and computational analytics, in building out the blue and green economies, in revolutionizing K-12 education, and in fast-tracking COVID-related research, that shows the greatest promise.

And there may be no other university better positioned than ours, to accelerate efforts to reimagine online education, and students educational experiences.

We have the experts right here: the best cinema school, the best gaming program, the most original technology for virtual reality, the best communications school, and extraordinary innovators in Viterbi, Iovine and Young, Rossier, Dornsife, Roski, and so on.

We sit at the epicenter of the imagination economy, and have extraordinary storytellers and technology leaders, who can bring education to life.

A great example of this is Dimensions in Testimony at the USC Shoah Foundation, a 3D educational experience, that is among the best in the world.

If we come together, and use the talent and tools we have, here and in Los Angeles, we can create a student experience unique to USC, that is second to none.

Underpinning these four goals, is our commitment to maintaining the highest ethical standards, in everything we do as a university.

Past scandals tarnished our reputation, and caused so much pain, across the Trojan community.

I spent a great deal of time this year listening, to students, faculty, alumni, and friends of USC, who shared their thoughts, on how we could bring back the luster to our university. I probably interacted with more than 40,000 people, and it was a wonderful, reaffirming experience.

Weve taken important, decisive steps this year in compliance, accountability, and transparency and we will continue these efforts, to ensure we stay on the right track going forward.

As we talk about the future, youre probably wondering what a post-COVID USC will look like. The pandemic will eventually subside, and when it does, well be ready.

Weve already launched Project Restart and are deep into planning for everyones return.

Schools are running full speed this summer online, and adding exciting new opportunities, and were re-building our infrastructure, to support more innovation and flexibility, when we do return.

Our decisions, about when and how to return, will be informed by a team of our leading public health professionals, along with state guidance and teams of experienced folks on our campuses.

Originally posted here:
State of the University Address - USC News

Ramona resident seeks speedy FDA approval for COVID-19 stem cell treatment – The San Diego Union-Tribune

Ramona resident Bob Harman is applying his expertise in the veterinary and biotech fields toward developing a stem cell treatment for COVID-19.

As CEO of Personalized Stem Cells, Inc. in Poway, Dr. Harman is involved in the companys quest to have the Food & Drug Administration (FDA) fast-track its Investigational New Drug application for the treatment of COVID-19 patients with stem cells.

Personalized Stem Cells parent, VetStem Biopharma, has provided stem cells for treatment of more than 15,000 dogs and horses and for treatment of animals at the San Diego Zoo, Safari Park and at SeaWorld.

Personalized Stem Cells has provided stem cells for an FDA approved human clinical trial for treatment of knee arthritis. Future stem cell clinical trials are planned for back pain, Traumatic Brain Injury, and opioid addiction.

Harmans own work with stem cells dates back to the 2007 Witch Creek fire when two of his horses were caught in a burning horse trailer in Ramona. The horses suffered severe smoke inhalation, but Harman said after he treated them with stem cells there were no signs of lung damage.

Personalized Stem Cells is developing a stem cell treatment for COVID-19 patients.

(Richard Deomampo - The Right Light)

Fast-forward 13 years and Harman sees the same possibilities to repair damaged lungs in COVID-19 patients using stem cells. Harman said the FDA is currently reviewing the Investigational New Drug application for its stem cell therapy in COVID-19 patients.

At the encouragement of the White House Coronavirus Task Force, Personalized Stem Cells has applied to the FDAs Coronavirus Therapeutic Accelerator Program which could expedite clinical trials.

If the FDA approves the application, which Harman foresees as imminent, Personalized Stem Cells would initiate a clinical trial to test the effectiveness of stem cells in COVID-19 patients.

Harman anticipates the first 20 patients in the CoronaStem 1 trial could be treated late this week or early next week at Sharp Grossmont Hospital in La Mesa, pending approvals.

Personalized Stem Cells also plans to ask the FDA to allow compassionate use of the stem cell treatment, which Harman said would provide early and widespread access to the treatment without clinical trials.

Here at Poway, we can make doses to treat 10,000 patients each month if approved by the FDA, Harman said.

Personalized Stem Cells has filed for expedited FDA approval to treat COVID-19 patients.

(Richard Deomampo - The Right Light)

The CEO said other companies developing similar but different stem cell treatments in Australia, China and Israel have demonstrated striking results in COVID-19 patients in intensive care units. He said stem cells have been injected intravenously to allow the stem cells to enter the lungs where they help reduce inflammation and damage to the patients lungs. Harman cites a 50 percent to 90 percent reduction rate in patient deaths related to COVID-19 in these countries.

Ventilators are not the solution to treating patients, he said, because as many as 90 percent of COVID-19 patients die while connected to ventilators.

Everybody talks about the need to manufacture ventilators, he said. Thats a last-ditch effort. Once youre on a mechanical ventilator its bad news. Ive never seen anything as dramatic as the possibilities for using stem cells to treat COVID-19.

The treatment Personalized Stem Cells is developing could also potentially be used to treat influenza patients and those affected by other virus outbreaks in the future, he said.

Personalized Stem Cells method of growing stem cells starts by collecting cells from adult fat tissue. Harman explained that donors supply the cells through liposuction procedures. The cells are tested to ensure they are disease-free and are then grown in sterile clean rooms. He said the cells will multiply, creating a large volume of stem cells that are packaged and frozen so they can be stored up to 20 years.

If and when the CoronaStem 1 trial is completed, which Harman estimates at the earliest could be within 90 days, the company would apply to the FDA to conduct a larger CoronaStem 2 trial possibly involving other hospitals in California. Depending on how well the stem cells perform in the first phase of study, the FDA could also approve widespread distribution of Personalized Stem Cells treatment.

Harman predicts that there may be a downward trend in COVID-19s spread by early summer, but he expects it will continue to linger.

The prediction that by summer this will be on a downturn is very real as long as we keep up appropriate safety measures, he said. I think we will see that by early summer it will slow down, but it wont be gone. Its not just going to disappear. It doesnt go away easily.

Personalized Stem Cells and VetStem Biopharma, which have 31 employees combined, are actively pursuing grants and donations to prepare for ramped up production of stem cells. Calidi Biotherapeutics is collaborating with Personalized Stem Cells to provide needed cell lines and supplies to speed stem cell manufacturing. But money is also needed to pay the doctors, nurses, imaging technicians, laboratories and others involved in performing the medical procedures for the clinical trial. In addition to seeking government grants, Personalized Stem Cells is reaching out to philanthropic groups such as the Gates Foundation and is partnering with the nonprofit The San Diego Foundation to accept donations.

Everyone wants to help, and this is something very tangible that you can do, Harman said. We are raising additional capital to be able to provide stem cell therapy to a wider population and potentially to underserved groups.

More information is available online at https://personalizedstemcells.com/covid-19/.

Read the original here:
Ramona resident seeks speedy FDA approval for COVID-19 stem cell treatment - The San Diego Union-Tribune

2 Types of Rituximab Combinations Effective in Transplant-Eligible Patients With Mantle Cell Lymphoma – AJMC.com Managed Markets Network

A new pooled analysis of rituximab/bendamustine and rituximab/cytarabine in transplant-eligible patients with mantle cell lymphoma (MCL) finds it leads to durable positive results in most patients.

A growing body of research has suggested that novel induction regimens followed by ASCT can improve outcomes in treatment-eligible patients with MCL. However, a team of investigators from multiple institutions wanted to get a better understanding of the efficacy and long-term success rate of rituximab/bendamustine and rituximab/cytarabine (RB/RC) specifically. To do so, they conducted a pooled analysis of patients in separate phase 2 trials at Dana-Farber Cancer Institute (DFCI), in Boston, and Washington University, in St. Louis, as well as a retrospective series of transplant-eligible MCL patients who received RB/RC as an off-trial, first-line therapy at DFCI. The investigators also performed minimal residual disease (MRD) testing in a subset of patients. Altogether, 88 patients were involved in the study, which was published in Blood Advances.

The analysis showed that 92% of patients completed induction, and 84% underwent planned consolidative ASCT. The most common grade 3 or 4 adverse events among the patients was lymphopenia (88%), thrombocytopenia (85%), and neutropenia (83%). There were no treatment-related deaths.

The therapy had an end-of-induction overall response rate of 97% and a complete response rate of 90%. After 33 months, 83% achieved 3-year progression-free survival, and the overall survival rate was 92%. MRD occurred in just 1 patient after ASCT. The patient subsequently relapsed.

Corresponding author Eric Jacobsen, MD, of DFCI, and colleagues, wrote that the therapy was generally well-tolerated, and the RB/RC induction therapy did not impair the successful collection of autologous stem cells, though some patients experienced delayed platelet recovery after ASCT, especially patients who received 3 g/m2 cytarabine and/or alternating cycles of RB/RC.

Since neither higher cytarabine doses nor alternating cycles of RB/RC were associated with improvement in response rates or PFS, we would recommend sequential cycles of RB/RC with 2 g/m2 doses of cytarabine for clinical practice for future trials that adopt this regiment, Jacobsen and colleagues wrote.

While acknowledging that pooling of clinical trial patients with off-trial patients can lead to potential issues, such as selection bias, Jacobsen and colleagues note that the overall 3-year progression-free survival rate of 83% compares favorably with cytarabine-based induction regimens. They also write that the fact that roughly half of the patients in the study took the RB/RC therapy off-trial suggests that it will perform well in a real-world clinical setting.

These patients had low rates of treatment discontinuation due to toxicity and achieved similarly durable remissions, suggesting that RB/RC is an effective choice of induction therapy for transplant-eligible patients outside of a clinical trial, they write.

Jacobsen and colleagues say the use of MRD as a primary endpoint is becoming more and more common, as is the use of MRD measurement as a tool for tailoring the frontline treatment. In the study, the authors found that IgNGS (ClonoSeq) was feasible for most patients.

While additional events and longer follow-up are necessary, our results suggest that IgNGS could be a useful tool for tracking MRD following ASCT and predicting impending recurrence, they write.

Reference

Merryman RW, Edwin N, Redd R, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv 2020;4 (5): 858867. doi: 10.1182/bloodadvances.2019001355.

See the original post:
2 Types of Rituximab Combinations Effective in Transplant-Eligible Patients With Mantle Cell Lymphoma - AJMC.com Managed Markets Network

Health: Mesoblast pushes ahead to the next stage of testing for stem cell COVID-19 treatment – Stockhead

Cellular medicine company Mesoblast Limited (ASX:MSB) has moved onto phase two (out of three) for its COVID-19 treatment, after getting promising initial results on US patients with moderate to severe symptoms.

The company wants to find out whether its stem cell treatment remestemcel-L will provide a survival benefit for moderate/severe acute respiratory distress syndrome caused by the virus.

The treatment was initially deployed on emergency compassionate grounds for COVID-19 patients in New York.

Alex Waislitz-backed Mesoblast is seeing if stem cells can help with COVID-19

Based on the results of those treatment rounds, Mesoblast now wants to definitively determine whether the use of remestemcel-L can help reduce mortality rates for COVID-19 patients who are already on ventilators, CEO Dr Silviu Itescu said.

Over 20 medical centres in the US will participate in the trial, which will complete enrolment in three to four months. Interim results may provide a guide to the market as to whether the treatment is effective, or futile.

To obtain statistical significance in accordance with FDA guidelines, Mesoblast will conduct a placebo-controlled trial on up to 300 ventilator-dependent patients in intensive care units with moderate to severe coronavirus symptoms.

Patients will receive either two intravenous infusions of remestemcel-L within five days, or a placebo. Measures for changes in overall mortality rates will then be taken within 30 days of the random test.

Secondary measures will then be taken to calculate the number of days patients are taken off ventilator support.

Shares in minnow health tech company Medibio (ASX:MEB) ticked higher by more than 30 per cent, after the company announced it had successfully lodged its 510k application with the US Food & Drug Administration (FDA).

The application is for the companys MEBsleep product, which uses artificial intelligence and neural network methodology to identify changes in the five stages of sleep necessary to diagnose sleep disorders.

Chief medical officer Dr Archie Defillo said the application was made on time and below budget. As part of the application process, Defillo said MEBsleep results received 85 per cent overall agreement with a consensus panel of certified sleep technicians.

Get the latest Stock & Small Caps news and insights direct to your inbox.

View original post here:
Health: Mesoblast pushes ahead to the next stage of testing for stem cell COVID-19 treatment - Stockhead

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia – BioSpace

HOUSTON, April 29, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.(Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that theUnited States Food and Drug Administration(FDA) Office of Orphan Products Development has granted Orphan Drug designation to MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product for the treatment of patients with acute myeloid leukemia (AML), following allogeneic stem cell transplant.

"We are pleased that theFDAhas granted orphan designation to MT-401, our novel MultiTAA-specific T cell product candidate and believe it is supportive of its potential to treat post allogeneic stem cell transplant patients with AMLa devastating and pervasive blood disease with a high medical need for a treatment. In investigator-sponsored trials, our MultiTAA-specific T cell product candidate was well-tolerated and we have observed clinical benefit across various liquid and solid tumors, suggesting the product candidate's ability to induce a patient's own T cells to expand for a more durable anti-tumor effect. We look forward to initiating our Company-sponsored Phase 2 study in patients with post allogeneic stem cell transplant AML," said Peter L. Hoang, President & CEO of Marker Therapeutics.

Orphan designation is granted by theFDA Office of Orphan Products Developmentto advance the evaluation and development of safe and effective therapies for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the U.S. Under the Orphan Drug Act, theFDAmay provide grant funding toward clinical trial costs, tax credits,FDAuser-fee benefits, and seven years of market exclusivity inthe United Statesfollowing marketing approval by theFDA. The granting of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval. For more information about orphan designation, please visit theFDAwebsite atwww.fda.gov.

About Marker Therapeutics, Inc.Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts

Forward-Looking Statement Disclaimer

This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the potential benefits of orphan drug designation; and the timing and success of our clinical trials, as well as clinical trials conducted by our collaborators. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-receives-fda-orphan-drug-designation-for-its-multi-antigen-targeted-t-cell-therapy-for-acute-myeloid-leukemia-301049675.html

SOURCE Marker Therapeutics, Inc.

Continued here:
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia - BioSpace

Hemostemix Announces the Appointment of David Tsubouchi to its Board of Advisors – Yahoo Finance

Calgary, Alberta--(Newsfile Corp. - April 30, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of David H. Tsubouchi, B.A., J.D., LL.D., D.S.Litt., C.Dir. to its Board of Advisors.

David Tsubouchi is the first Japanese Canadian to be elected to any provincial legislature in Canada and to be appointed as a Cabinet Minister. He has served as the Minister of Consumer and Commercial Relations, Solicitor General, Chair of Management Board and Minister of Culture. Mr. Tsubouchi sits on the boards of OMERS Pension Fund, Lakefront Utilities and the Ontario Arts Council. He has previously served as the Honourary Consul General of Mongolia. As the former Registrar and CEO of the Ontario College of Trades he oversaw the regulation of the skilled trades in Ontario. He has also served as the Integrity Commissioner for the Town of Richmond Hill. His book, Gambatte was nominated for the Speaker's Book Award and the Heritage Toronto Book Award.

"Our team is delighted to be working closely with and taking counsel from David Tsubouchi, as his breadth of experience and relationships of trust span our legal, political, business and finance sectors," said Thomas Smeenk, President & CEO.

"I am looking forward to working with Thomas Smeenk and advising the team at Hemostemix," said David Tsubouchi. "Healthcare is and will continue to be a priority of not only Canada but of the world. An entrepreneurial Canadian stem cell company that has global aspirations and a public good purpose to improve the quality of life of many will be inspirational and exciting to work with," Mr. Tsubouchi said.

ABOUT HEMOSTEMIX

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit http://www.hemostemix.com.

Contact: Thomas Smeenk, President, CEO & Co-FounderTSmeenk@Hemostemix.com 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. By their nature forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company's ability to fund operations and access the capital required to continue operations, the Company's stage of development, the ability to complete its current CLI clinical trial, complete a futility analysis and the results of such, future clinical trials and results, long-term capital requirements and future developments in the Company's markets and the markets in which it expects to compete, risks associated with its strategic alliances and the impact of entering new markets on the Company's operations. Each factor should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. Additional information identifying risks and uncertainties are contained in the Company's filing with the Canadian securities regulators, which filings are available at http://www.sedar.com.

Story continues

Continued here:
Hemostemix Announces the Appointment of David Tsubouchi to its Board of Advisors - Yahoo Finance

Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval -…

SAN CARLOS, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- BioCardia, Inc.[Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported that it has accepted and implemented FDA-recommended modifications to the primary endpoint for the CardiAMP Cell Therapy Heart Failure Trial and associated statistical analysis plan. The Agency proposed these modifications to support the potential for marketing approval for the therapy based on the currently enrolling pivotal trial.

The primary endpoint going forward will be an outcomes composite score based on a three-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis, an established outcomes design that has been used in other leading heart failure programs. The FS procedure is a ranked analysis that first compares each subject to each other subject for occurrence of first-tier events (time to death, in this case) and then compares patient outcomes for subsequent tiers. The tiers, starting with the most serious events, would be (1) all-cause death, including cardiac death equivalents such as heart transplant or left ventricular assist device placement, ordered by time to event; (2) non-fatal Major Adverse Coronary and Cerebrovascular Events (MACCE), excluding those deemed procedure-related occurring within the first seven days post-procedure (heart failure hospitalization, stroke or myocardial infarction), ordered by time to event, and (3) change from baseline in Six Minute Walk Distance at 12 months.

BioCardia CEO Peter Altman, PhD, said, The only major modification to our previous endpoint is that patients who experience a MACCE event and recover will not be factored into the benefit seen in the third-tier measure of Six Minute Walk Distance at one-year follow-up. Since we saw no incidence of MACCE at one year among treated patients in our Phase II trial, our probability of achieving a positive result in the primary endpoint in the ongoing pivotal CardiAMP Heart Failure trial remains unchanged, at greater than 95 percent. Because the FS composite outcomes endpoint is already established for heart failure trials, we expect it to significantly enhance understanding and confidence in our trial results among physicians and payers alike.

The CardiAMP Heart Failure Trial is studying CardiAMP cell therapy, an autologous bone marrow-derived mononuclear cell formulation designed to stimulate the bodys natural healing response in treating heart failure which develops after a heart attack. The trial is evaluating the cell therapys ability to improve patient survival, exercise capacity and quality of life, as well as its safety. The CardiAMP Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively select patients based on cell potency to maximize the probability of patient benefit.

The ongoing multi-center, double-blinded, randomized (3:2), controlled pivotal CardiAMP Heart Failure Trial is expected to enroll 260 patients at up to 40 centers nationwide. The national co-principal investigators are Amish Raval, MD, of the University of Wisconsin and Carl Pepine, MD, of the University of Florida, Gainesville. In March 2020, the Data Safety Monitoring Board indicated there were no safety concerns with the CardiAMP study results and recommended that the trial continue, as planned.To date, 74 patients have been enrolled at 25 active centers. The trial is sponsored, in part, by the Maryland Stem Cell Research Foundation and has reimbursement from the Centers for Medicare and Medicaid Services (CMS).

For additional resources and to learn more about the CardiAMP Heart Failure Trial, visit http://www.biocardia.com.

About BioCardiaBioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP and CardiALLO cell therapies are the Companys biotherapeutic product candidates in clinical development. The Company's approved products include the Helix transendocardial delivery system and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix System and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.

Forward Looking Statements This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, the intended outcomes of our trials, the availability of data from our clinical trials, filings with the FDA, FDA product clearances, the efficacy and safety of our products and therapies and statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardias business and product development plans and overall market conditions. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardias Form 10-K filed with the Securities and Exchange Commission on April 9, 2020, under the caption titled Risk Factors. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact: Michelle McAdam, Chronic Communications, Inc.Email:michelle@chronic-comm.comPhone: 310-902-1274

Investor Contact: David McClung, Chief Financial OfficerEmail:investors@BioCardia.comPhone: 650-226-0120

Read more here:
Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval -...

Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL – Cancer Therapy Advisor

A novel,bispecific CD19/CD22 chimeric antigen receptor T-cell (CAR-T) therapy wastolerable and resulted in responses among patients with acute lymphoblasticleukemia (ALL), according to results from a phase 1 trial presented at the AmericanAssociation for Cancer Research (AACR) Virtual Annual Meeting I 2020.

Thenovel CAR-T therapy was developed with the hypothesis that dual antigen-targetingstrategies may prevent antigen negative escape, Haneen Shalabi, DO, of theNational Cancer Institute and lead author and presenter of the study, said.

Thephase 1, dose-escalation study treated 13 young patients with ALL with theCD19/CD22 CAR-T therapy at 3 different dose levels, including 3 x 105,1 x 106, and 3 x 106. The bispecific construct containedFMC63 (CD19 scFv) linked with m971 (CD22 scFv) and a 4-1 BB costimulatorydomain.

Patientsunderwent lymphodepletion with fludarabine plus cyclophosphamide prior to theirCAR-T infusion. The primary endpoints were safety and toxicity, and thesecondary endpoints were efficacy, chimeric antigen receptor (CAR) expansion,and CAR persistence.

Atbaseline, the median age was 19.6 (range, 5.4-28.5). Patients had receivedprevious treatments, including hematopoietic stem cell transplant (54%),CD19-targeted therapy (69%), prior CD19 CAR T cell therapy (38.4%),blinatumomab (61.5%), CD22-targeted therapy (38.4%), inotuzumab (30.7%), andCD22 CAR-T therapy (15.4%). Extramedullary disease was present in 46.2% ofpatients.

CAR Tcells were well tolerated and toxicities were reversible in all patients, DrShalabi said.

Cytokinerelease syndrome (CRS) developed in 46% of patients, 15.4% of which was grade 3or higher. Both patients who developed grade 3 or higher CRS had received the 1x 106 dose level of the CD19/CD22 CAR-T product and both requiredtreatment with tocilizumab. One patient developed neurotoxicity, and hadreceived the 3 x 106 dose level.

Of the12 patients evaluable for efficacy, a complete response (CR) was achieved by42% (5) of patients, including all patients who received the 1 x 106 or 3 x 106 dose levelsof the CD19/CD22 CAR-T therapy. There were 2 nonresponders.

Two patientswho received 1 x 106 CAR-T and all patients who received the 3 x 106dose level were negative for minimal residual disease (MRD), with the remainingCRs demonstrating bone marrow clearance. Four of the 5 patients who were MRDnegative were also naive to CAR-T therapy.

Of the 5patients who achieved a CR, 2 relapsed with CD19-positive/CD22-positive diseaseand 3 remained in remission at a median 7 months after CAR T cell infusion.

Severalpatients, however, who were MRD negative in the bone marrow did not achieve CRin their extramedullary disease. Dr Shalabi said that these discrepant resultsbetween marrow and extramedullary disease suggests potentially limited CAR-Ttrafficking to sites of extramedullary disease. She suggested that treatmentat higher dose levels may be needed to overcome this limitation.

CAR T-cellexpansion occurred in all patents who responded, with a median peak inperipheral blood of 7%. At day 28, there were 1.3% CAR T cells in the bonemarrow. The persistence of the CAR T cells in peripheral blood was a median of45.6 days, as measured by flow cytometry.

Dr Shalabi concluded that this early experience with bispecific CD19/CD22 CAR T cells demonstrates clinical activity with reversible CRS and limited neurotoxicity. She noted that future studies will explore a 1 x 107 dose level, intensification of lymphodepletion prior to CAR-T infusion, and consideration of the potential role of immune checkpoint inhibitors to augment CAR-T in extramedullary disease.

Read more of Cancer Therapy Advisors coverage of AACR 2020 meeting by visiting the conference page.

References

Shalabi H, Yates B, Shahani S, et al. Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL. Presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting I 2020; April 27-28, 2020. Abstract CT051.

Originally posted here:
Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL - Cancer Therapy Advisor